Board of Trustees of the University of Arkansas

The Texas A&m University System

University of Guelph

Sherryll Layton

Billy M Hargis

Luc Berghman

Young Min Kwon

Walter G Bottje

Mandy Cox

Kimberly Cole

Neil R Pumford

Lisa Bielke

Olivia B Faulkner

John R Barta

Guillermo Tellez

Daad Abi-Ghanem

Saeed El-Ashram

Said El-Ashram

Walter Bottje

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.

Compositions and methods of enhancing immune responses to enteric pathogens

Vaccine vectors and methods for enhancing resistance toinfection or for enhancing the immune response toare provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO:-or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

Vaccine and methods to reduce campylobacter infection

Vaccines comprising TRAP polypeptides andvectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.

Compositions and methods of enhancing immune responses to

Compositions and methods of enhancing immune responses to Eimeria

Provided herein are13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.

Compositions and methods of enhancing immune responses

Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.

Vaccine vectors and methods of enhancing immune responses

Vaccines comprising fliC and CD 154 polypeptides andvaccine vectors comprising fliC polypeptides are provided. Also provided arc methods of enhancing an immune response against flagellated bacteria and methods of reducing morbidity associated with infection with flagellated bacteria.

Compositions and methods of enhancing immune responses to flagellated bacterium

Vaccine vectors and methods for enhancing resistance toinfection or for enhancing the immune response toare provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

[object Object]

Provided herein are13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.

Growing community of inventors

Rogers, AR, United States of America

Sherryll Layton